IDEAYA Biosciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $6.6M | $207.8M | $7.0M | $0 | $0 | $0 | $3.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $108.7M | $95.7M | $83.0M | $140.2M | $57.2M | $54.5M | $42.8M | $38.8M |
| SG&A Expense | $22.5M | $19.4M | $16.4M | $11.0M | $9.7M | $10.4M | $8.2M | $7.1M |
| Operating Income | $-122.3M | $-108.5M | $108.5M | $-144.1M | $-66.9M | $-64.9M | $-51.0M | $-41.9M |
| Operating Margin | -1,380.7% | -1,654.6% | 52.2% | -2,059.1% | — | — | — | -1,068.4% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-112.5M | $-98.5M | $119.2M | $-130.3M | $-51.8M | $-52.8M | $-39.6M | $-34.0M |
| Net Margin | -1,269.6% | -1,502.1% | 57.4% | -1,861.6% | — | — | — | -865.5% |
| EPS (Basic) | $-1.22 | $-1.11 | $1.35 | $-1.55 | $-0.60 | $-0.68 | $-0.53 | $-0.51 |
| EPS (Diluted) | $-1.22 | $-1.11 | $1.33 | $-1.55 | $-0.60 | $-0.68 | $-0.53 | $-0.51 |
| Shares Outstanding (Basic) | 92.1M | 88.7M | 88.5M | 81.7M | 86.2M | 78.0M | 75.1M | 57.5M |
| Shares Outstanding (Diluted) | 92.1M | 88.7M | 89.7M | 81.7M | 86.2M | 78.0M | 75.1M | 57.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |